Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Harrow Health Inc
HROW | US
33.28
USD-1.13
-3.28%
HROW | US
About Harrow Health Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
20/03/2026
Close
33.28
Open
34.32
High
34.85
Low
33.06
Harrow Health Inc. an eyecare pharmaceutical company focuses on the discovery development and commercialization of ophthalmic therapies. The company offers ImprimisRx an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe; TRIESENCE a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100 a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals Inc. and changed its name to Harrow Health Inc. in December 2018. Harrow Health Inc. was founded in 1998 and is headquartered in Nashville Tennessee.
View LessHROW | US
Risk
100.7
Sharpe
0.26
Luna's Score
34/100
Recommendation
Sell
Luna says (HROW | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
42.2%1 month
100.7%3 months
77.0%6 months
70.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
34.20
Debt to equity
3.31
Debt to assets
0.63
Ent. to EBITDA
861.59
Ent. to rev.
13.77
PEG
-
Other Fundamentals
EBITDA
3.19M
MarketCap
1.18B
MarketCap(USD)
1.18B
Div. yield
-
Op. margin
3.13
Erngs. growth
-64.00
Rev. growth
46.20
Ret. on equity
-83.70
Short ratio
10.78
Short perc.
16.29
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
4.28
Range1M
21.43
Range3M
21.79
Volumes: Market Activity
Rel. volume
0.98
Price X volume
33.57M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 861.59 | - | Expensive |
| Ent. to Revenue | 13.77 | - | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 34.20 | 13.15 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 76.97 | - | Par |
| Debt to Equity | 3.31 | -1.88 | Expensive |
| Debt to Assets | 0.63 | 0.48 | Expensive |
| Market Cap | 1.18B | - | Emerging |
